Anti Inflammatory News and Research

RSS

McMaster Team Identifies Natural Immune Defense Against Advanced Fatty Liver Disease

Researchers at McMaster University have discovered that a naturally occurring hormone best known for suppressing appetite and promoting weight loss also helps protect the liver from inflammation through a previously unknown signaling pathway, opening new possibilities for treating advanced fatty liver disease.

11 Aug 2026

Study Identifies miR-16 as a Robust Marker of Muscle Wasting

Cachexia-a syndrome characterized by progressive muscle wasting-affects both humans and dogs with chronic diseases such as cancer.

22 Jul 2026

Study Identifies Immune Cell Failures as Aging Drivers

We may age at different rates, but none of us escapes aging.

17 Jul 2026

GLP-1 Drugs Show Promise Against Long COVID-Related Lung Scarring

GLP-1 agonists have gained widespread use for managing weight loss and type 2 diabetes, with recent research indicating additional health advantages.

13 Jul 2026

Novel Study Reveals Hidden Biological Drivers Behind Cancer Induced Appetite Loss

Cachexia is a condition in which patients affected by cancer or other chronic diseases become sick and lose weight. The condition often involves brain-related symptoms of sickness, such as loss of appetite, which can lead to loss of muscle and often fat.

10 Jul 2026

Cancer Cells Hijack Macrophage Metabolism to Create an Immunosuppressive Tumor Microenvironment

Tumor-associated macrophages (TAMs) are among the most abundant immune cells in the tumor microenvironment. However, instead of attacking cancer cells, they are typically co-opted to support tumor growth, metastasis, and therapeutic resistance.

2 Jul 2026

Taste and Smell Genetic Receptors Shape Long-Term Disease Risks

Imagine if a doctor could look at your DNA and predict not just your disease risk, but also which foods you're drawn to – and whether those cravings are quietly protecting you.

19 Jun 2026

Indiana University Study Identifies New Pathway to Combat Leukemia

Indiana University School of Medicine cancer researchers have identified a potential way to use existing, accessible drugs to combat juvenile myelomonocytic leukemia (JMML) by targeting a specific inflammatory pathway.

19 Jun 2026

Scientists Discover Genetic Root of Rare Childhood Inflammatory Skin Disorder

An international team of researchers has identified a genetic cause for a rare inflammatory skin condition.

15 Jun 2026

Study Shows Protein Fragment Reduces Neuronal Degeneration in Mice

Researchers at the Federal University of São Paulo (UNIFESP) in Brazil have discovered a new strategy that may protect neurons and other brain cells involved in Parkinson's disease in the future.

13 Jun 2026

Body Clock Protein Drives Macrophages Into Pro-Inflammatory States

Daily life is shaped by the solar day, influencing when we wake up, eat, work, and sleep. Inside the body, a similar internal timing system -present in nearly every cell- known as the circadian clock, synchronizes many biological functions such as sleep, metabolism, hormone release, and even the immune system's activity.

12 Jun 2026

New 3D Cortical Tissue Models Incorporate Microglia to Bridge Preclinical Translation Gaps

28bio today announced CNS-3D Inflammatory Organoids, designed to evaluate efficacy of anti-inflammatory drugs by quantifying their ability to reduce inflammatory injury, preserve tissue health, and restore neuronal network activity.

20 May 2026

New 3D Human Liver Model Mimics Chronic Disease For 30 Days

Researchers developed a 3D liver model that functions for a month, replicating inflammation and fibrosis, crucial for studying liver diseases and therapies.

19 May 2026

MRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative Colitis

MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that MH002, the Company’s lead rationally designed Live Biotherapeutic Product (LBP) candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate ulcerative colitis (UC).

From MRM Health NV 4 May 2026